1. Home
  2. GSIW vs PPBT Comparison

GSIW vs PPBT Comparison

Compare GSIW & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GSIW

Garden Stage Limited

HOLD

Current Price

$0.14

Market Cap

28.6M

Sector

N/A

ML Signal

HOLD

Logo Purple Biotech Ltd.

PPBT

Purple Biotech Ltd.

HOLD

Current Price

$0.68

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GSIW
PPBT
Founded
2016
2010
Country
Hong Kong
Israel
Employees
17
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.6M
7.5M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
GSIW
PPBT
Price
$0.14
$0.68
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
329.0K
783.0K
Earning Date
01-01-0001
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,368,221.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
283.23
N/A
52 Week Low
$0.09
$0.53
52 Week High
$1.79
$5.20

Technical Indicators

Market Signals
Indicator
GSIW
PPBT
Relative Strength Index (RSI) 39.31 40.73
Support Level $0.13 $0.72
Resistance Level $0.14 $0.87
Average True Range (ATR) 0.01 0.05
MACD -0.00 -0.01
Stochastic Oscillator 18.97 15.60

Price Performance

Historical Comparison
GSIW
PPBT

About GSIW Garden Stage Limited

Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

Share on Social Networks: